NCT04604509View on ClinicalTrials.gov

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

2,010

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Cigarette Smoking-Related Carcinoma
Interventions
DRUG

Bupropion Hydrochloride Controlled-release

Given PO

DRUG

Nicotine Replacement

Given via nicotine patch, lozenges, or gum

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Tobacco Cessation Counseling

Receive behavioral smoking cessation counseling

DRUG

Varenicline

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER